Connor, Clark & Lunn Investment Management (CC&L)’s PMV Pharmaceuticals PMVP Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$40.3K	Buy	+32,460	New	+$41.3K	﹤0.01%	1520
2025 Q2	–	Sell	-267,636	Closed	-$292K	–	1644
2025 Q1	$292K	Sell	267,636 -103,284	-28%	-$140K	﹤0.01%	1255
2024 Q4	$560K	Sell	370,920 -70,104	-16%	-$111K	﹤0.01%	1121
2024 Q3	$657K	Buy	441,024 +1,885	+0.4%	+$2.91K	﹤0.01%	1019
2024 Q2	$711K	Buy	439,139 +5,286	+1%	+$9.53K	﹤0.01%	945
2024 Q1	$738K	Buy	433,853 +248,730	+134%	+$465K	﹤0.01%	980
2023 Q4	$574K	Buy	185,123 +15,424	+9%	+$40.8K	﹤0.01%	1008
2023 Q3	$1.04M	Buy	169,699 +5,737	+3%	+$39.4K	0.01%	806
2023 Q2	$1.03M	Buy	163,962 +7,904	+5%	+$41.4K	0.01%	788
2023 Q1	$744K	Buy	156,058 +40,369	+35%	+$284K	﹤0.01%	795
2022 Q4	$1.01M	Buy	+115,689	New	+$1.23M	0.01%	703

Other funds holding PMVP

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PMVP Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in PMV Pharmaceuticals (PMVP) in Q1 2026: 32,460 shares worth $40.3K. The stake represents ﹤0.01% of the portfolio and ranks #1520 among its holdings. This is a return to the name: Connor, Clark & Lunn Investment Management (CC&L) previously reported a position in PMVP as recently as Q1 2025.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PMVP in Q4 2022 and has held it in 11 quarters since. The position peaked at $1.04M in Q3 2023. 69 funds tracked by Wall St. Rank hold PMVP as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 32,460 shares of PMV Pharmaceuticals worth $40.3K as of Q1 2026.
PMV Pharmaceuticals was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q1 2026.
PMV Pharmaceuticals made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1520 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PMV Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s PMV Pharmaceuticals position peaked at $1.04M in Q3 2023.
69 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.